GEN Exclusives

More »

GEN News Highlights

More »
Mar 14, 2007

Advanced Life Sciences’ Prophylactic for Inhaled Anthrax Granted Orphan Drug Designation

  • Advanced Life Sciences Holdings’ cethromycin received Orphan Drug Designation for the prophylactic treatment of patients exposed to inhalation anthrax. “This designation will benefit us as we continue to build the cethromycin safety and efficacy database and will ultimately help position cethromycin as a potentially important antibiotic for the U.S. government's Strategic National Stockpile," says Michael T. Flavin, Ph.D., chairman and CEO.

    The company’s cethromycin is a second-generation ketolide antibiotic. Cethromycin seems to have significant in vitro activity against over 30 anthrax (Bacillus anthracis) strains. Although it is still being tested in nonhuman primates to determine its potential efficacy as an inhalation anthrax prophylactic therapy, it is in late-stage evaluations for other indications. Cethromycin is in Phase III development for the treatment of respiratory tract infections and in pivotal Phase III trials for the treatment of mild-to-moderate community acquired pneumonia.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...

Unable to get Jobs Listings.

More »

GEN Poll

More » Poll Results »

Lab-Grown Vaginas

Which body part do you think will be successfully engineered in the lab next?